864754-22-3

Usage

Uses

Used in Medicinal Chemistry:
2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrazol-1-ylmethyl]-pyridine is used as a building block or intermediate in the synthesis of pharmaceutical compounds. Its unique structure and reactivity may contribute to the development of new drugs with specific therapeutic properties.
Used in Organic Synthesis:
In the field of organic synthesis, 2-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrazol-1-ylmethyl]-pyridine serves as a versatile reagent or precursor for the creation of a variety of organic molecules. Its structural features allow for further functionalization and modification, expanding the scope of organic chemistry.
Used in Material Science:
2-[4-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrazol-1-ylmethyl]-pyridine may also find applications in material science, where its unique properties could be harnessed to develop new materials with specific characteristics, such as improved stability, reactivity, or selectivity in various chemical processes.

InChI:InChI=1/C15H20BN3O2/c1-14(2)15(3,4)21-16(20-14)12-9-18-19(10-12)11-13-7-5-6-8-17-13/h5-10H,11H2,1-4H3

Upstream product

• 269410-08-4 pyrazole-4-boronic acid pinacol ester 
• 31106-82-8 2-(bromomethyl)pyridine hydrobromide 
• 6959-47-3 2-chloromethylpyridine hydrochloride 

Relevant academic research and scientific papers

Hetero-aromatic compound and its use in medicine (by machine translation)

The invention discloses heteroaromatic compound and its use in medicine, in particular, the invention provides a hetero-aromatic compound or its stereoisomers, geometric isomers, tautomers, racemate, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug, and containing said pharmaceutical composition; the invention also discloses the compound or its pharmaceutical compositions in use for preparing a medicament, and in the treatment of autoimmune diseases or proliferative diseases of application. (by machine translation)

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF

A compound represented by Formula [1] (in the formula, Z1 represents N, CH, or the like; X1 represents NH or the like; R1 represents a heteroaryl group or the like; each of R2, R3, and R4 represents a hydrogen atom, a halogen atom, an alkoxy group, or the like; and R5 represents a heteroaryl group or the like) or salt thereof.

3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS

The present application relates to novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives of formula (I), as protein kinase inhibitors. The invention particularly relates to compounds of formula (I), preparation of compounds and pharmaceutical compositions thereof. The invention further relates to pharmaceutically acceptable salts and compositions comprising the said novel 3-(pyrazolyl)-lH-pyrrolo[2,3-b]pyridine derivatives and their use in the treatment of various disorders.

PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, B, R1, R2, R3, R4a, R5, and Z are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as aurora.

Methods for inhibiting protein kinases

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevent

ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS

The present invention is directed to compounds of formula (I), wherein R1 is a ring and n is a number from 1 to 8. The invention also relates to use of the compounds in therapy as metabotropic glutamate receptor modulators, particularly in neurological and psychiatric disorders.